| Symbol | VVOS |
|---|---|
| Name | VIVOS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 9137 RIDGELINE BOULEVARD,SUITE 135, HIGHLANDS RANCH, Colorado, 80129, United States |
| Telephone | +1 844 672-4357 |
| Fax | — |
| — | |
| Website | https://www.vivos.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001716166 |
| Description | Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have been used to treat over 15,000 patients worldwide by more than 1,100 trained dentists. Additional info from NASDAQ: |
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Read moreVivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
Read moreNew Form SCHEDULE 13G/A - Vivos Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003625 <b>Size:</b> 10 KB
Read more(95% Neutral) VIVOS THERAPEUTICS, INC. (VVOS) Provides Update on Patent for children (ages 6-17)
Read moreNew Form SCHEDULE 13G - Vivos Therapeutics, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001851416-26-000026 <b>Size:</b> 9 KB
Read moreVivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
Read more(99% Neutral) VIVOS THERAPEUTICS, INC. (VVOS) Announces Executive Changes
Read moreSkaff Michael C 🟢 acquired 5.5M shares (3 derivative) of Vivos Therapeutics, Inc. (VVOS) at $0.46 ($2.5M) Transaction Date: Jun 30, 2026 | Filing ID: 304815
Read moreNew Form SCHEDULE 13D - Vivos Therapeutics, Inc. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001104659-26-083931 <b>Size:</b> 38 KB
Read moreNew Form 3 - Vivos Therapeutics, Inc. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001193125-26-304807 <b>Size:</b> 5 KB
Read more